Efficacy of convalescent plasma for the treatment of COVID-19 in lung transplant recipients: A multicenter French study - 17/12/24
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Riassunto |
Introduction |
Lung transplant (LT) recipients are at greater risk of complications from COVID-19. Treatment options are limited partly due to interactions with immunosuppressive agents. Convalescent plasma (CP) is a potential treatment option, but it has not been extensively studied in LT patients. We aimed to assess the efficacy and safety of CP use in France for COVID-19 infected LT patients.
Material and methods |
We retrospectively recruited LT patients followed up in the 10 French LT centers, older than 18 years, infected with SARS-CoV-2 between the pandemic onset and July 1, 2023, and treated with high-titer CP.
Results |
We collected the data from 27 patients who received CP for a COVID-19 infection in six out of the 10 French LT centers. The average delay between symptom onset and CP administration was 19.5 days, and 51.8 % of patients received four units. In patients treated within the first 9 days of infection, the survival rate was 100 % at one and three months vs. 75 % (p = 0.28) for late administration patients. Average loss of forced expiratory volume in 1 second at three months was 10.5 % in the early group vs. 3.3 % in the late group (p = 0.58). The average length of hospital stay was 18 and 24 days respectively (p = 0.07). Early use of CP was also more frequent in 2023.
Discussion |
In this study highlighting the French experience for the use of CP in LT patients, we observed a limited, heterogenous but well-tolerated use of this therapy.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Covid-19, Sars-cov-2, Lung transplantation, Convalescent plasma
Abbreviations : covid-19, cp, fev1, FVC, ICU, IQR, LT, SARS-CoV-2, SD, SOT
Mappa
Vol 87
Articolo 101145- maggio 2025 Ritorno al numero
Articolo precedente
- Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF) : Endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU)
- Aurélien Dinh, François Barbier, Jean-Pierre Bedos, Mathieu Blot, Vincent Cattoir, Yann-Erick Claessens, Xavier Duval, Pierre Fillâtre, Maxime Gautier, Yann Guegan, Sophie Jarraud, Alban Le Monnier, David Lebeaux, Paul Loubet, Constance de Margerie, Philippe Serayet, Yacine Tandjaoui-Lambotte, Emmanuelle Varon, Yves Welker, Damien Basille
- Tele-medicine experiences and expectations from patients with neuromuscular diseases treated with non-invasive ventilation
- Sandrine Segovia-Kueny, Mathieu Delorme, Caroline Stalens, Julie Lejeune, Frédéric Lofaso, Hélène Prigent, Antoine Leotard
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.